azd4547
Showing 1 - 11 of 11
Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)
Recruiting
- Urothelial Carcinoma
- AZD4547
- Tislelizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 8, 2023
Urothelial Carcinoma Trial in Shanghai (AZD4547)
Recruiting
- Urothelial Carcinoma
- AZD4547
-
Shanghai, Shanghai, ChinaFudan University Cancer Hospital
Oct 20, 2021
Muscle Invasive Bladder Cancer Trial in Worldwide (AZD4547, MEDI4736, Olaparib)
Active, not recruiting
- Muscle Invasive Bladder Cancer
- AZD4547
- +6 more
-
Los Angeles, California
- +26 more
Oct 17, 2022
NSCLC Metastatic Trial in France (AZD2014, AZD4547, AZD5363)
Active, not recruiting
- Non-small Cell Lung Cancer Metastatic
- AZD2014
- +10 more
-
Avignon, France
- +36 more
Jul 29, 2022
Metastatic Breast Cancer Trial in France (AZD2014, AZD4547, AZD5363)
Active, not recruiting
- Metastatic Breast Cancer
- AZD2014
- +18 more
-
Angers, France
- +24 more
Mar 8, 2022
NSCLC, Carcinoma, Squamous Cell, Adenocarcinoma Trial in United Kingdom (AZD4547, Vistusertib, Palbociclib)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +2 more
- AZD4547
- +10 more
-
Aberdeen, United Kingdom
- +24 more
Nov 2, 2021
Cancer, Advanced Solid Malignancies Trial in Worldwide (AZD4547)
Terminated
- Cancer
- Advanced Solid Malignancies
- AZD4547
-
Stanford, California
- +28 more
Nov 30, 2018
Recurrent NSCLC, Squamous Cell Lung Cancer Trial in United States (docetaxel, AZD4547)
Completed
- Recurrent Non-small Cell Lung Cancer
- Squamous Cell Lung Cancer
- docetaxel
- AZD4547
-
Atlanta, Georgia
- +4 more
Jan 26, 2018
Gastro-oesophageal Junction Cancer, Gastric Cancer Trial in Worldwide (AZD4547, paclitaxel)
Terminated
- Gastro-oesophageal Junction Cancer
- Gastric Cancer
- AZD4547
- paclitaxel
-
Brussels (Anderlecht), Belgium
- +60 more
Jan 16, 2017
Cancer, Advanced Solid Malignancies Trial in Chuo-ku, Nagoya-shi, Sapporo-shi (AZD4547)
Completed
- Cancer
- Advanced Solid Malignancies
- AZD4547
-
Chuo-ku, Japan
- +2 more
Jun 28, 2016
FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer Trial in Worldwide (AZD4547, Exemestane, Placebo)
Completed
- FGFR Inhibition, Pharmacokinetics, Biomarkers
- ER+ Breast Cancer
- AZD4547
- +3 more
-
Leuven, Belgium
- +20 more
Jan 13, 2016